AbbVie Migraine Career Catalyst Awardtm contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in ...

who is the The AbbVie Foundation Distinguished Service Professor of Obstetrics and Gynecology at the University of Chicago; ...

While Humira is losing steam after its patent expiration, AbbVie has prepared for a future beyond this blockbuster. It has ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

The article " High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight " first appeared on MarketBeat.

In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2, ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

AbbVie and Johnson & Johnson’s Imbruvica is in fifth place with sales expected to reach $11.9 billion by 2025. The drug has received FDA approval for multiple oncology indications and chronic ...

AbbVie is currently addressing serious health issues in the following six areas: hepatitis C virus, neuroscience, immunology, oncology, renal disease and women's health. Some of its current ...

BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline ... BeiGene may lose the lawsuit to AbbVie over Brukinsa and start to pay royalties, which lowers our ...